Catalent 2Q Revenues: $721.4 million (+16%) 2Q Earnings: $45.5 million (-6%) Comments: Growth in the quarter was primarily driven by the impact of its gene therapy acquisitions, as well as organic growth within the Biologics, Softgel and Oral Technologies, and Clinical Supply Services segments, offset by a decline in the Oral and Specialty Delivery segment. Revenue from the Softgel and Oral Technologies segment was $267.9 million, up 2%. Revenue from the Biologics segment was $225.2 ...